{'fraction_non_alphanumeric': 0.019661387220098307, 'fraction_numerical': 0.002730748225013654, 'mean_word_length': 5.450704225352113, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
OLIGOSACCHARIDES IN HUMAN MILK AND IN MILK FORMULAS FOR PRETERM INFANTS – VALUE FOR PRETERM INFANTS

Better long-term survival of very preterm infants depends on optimizing the methods of their nutritional support. Today it is widely recognized that mother’s breast milk is the optimal enteral food for this extremely vulnerable infant population, becausebreast milk feeding reduces their morbidity and mortality. The advantages of breast milkfeeding are related to the biologically active components of breast milk, especially oligosaccharides (OS),concentration of which is only less than amount of lactose and fat. Available experimental and clinical data suggest that the positive clinical effect of the OS can be mostly structure-specific, since the spectrum of human milk oligosaccharides (HMO) is quite wide and includes more than 200 known different compounds. The content of the OS in breast milk is individual and depends on many factors. Despite the emergence of the potential for industrial synthesis of several HMOs, there are currently no results of interventional clinical studies with the use of food products for preterm infants enriched with such OS. Instead, the available data prove positive clinical effects of enrichment of formulas and breast milkwith synthetic OS, which, by their biological properties, mimicHMO. The largest number of such scientific data exists with respect to a special complex of OS, consisting of short-chain galactooligosaccharides (scGOS) and long-chain fructooligosaccharides (lcFOS) in a ratio of 9:1 with the possible addition of galacturonic acid. The article presentscurrent data on functional biology of HMO, clinical effectiveness of the use of synthetic OS in preterm infants, as well as future challenges and opportunities associated with the clinical application of the OS.